Combination of topotecan and cisplatin in relapsed patients with small cell lung cancer : a phase II study of the hellenic cooperative oncology group (HeCOG)

To assess the safety and efficacy of a 3-day schedule of cisplatin and topotecan in patients with recurrent small-cell lung cancer (SCLC). Thirty-four relapsed patients were treated with cisplatin 20 mg/m2 and topotecan 0.9 mg/m2, both given on days 1-3 every 3 weeks, in a phase II study. Complete r...

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology 2006-02, Vol.57 (2), p.207-212
Main Authors: CHRISTODOULOU, Christos, KALOFONOS, Haralambos P, BRIASOULIS, Evangelos, BAFALOUKOS, Dimitrios, MAKATSORIS, Thomas, KOUTRAS, Angelos, SKARLOS, Dimosthenis V, SAMANTAS, Epaminondas
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic agents
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Carcinoma, Small Cell - drug therapy
Cisplatin - administration & dosage
Drug Administration Schedule
Female
Humans
Infusions, Intravenous
Lung Neoplasms - drug therapy
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Pneumology
Survival Analysis
Topotecan - administration & dosage
Treatment Outcome
Tumors of the respiratory system and mediastinum
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To assess the safety and efficacy of a 3-day schedule of cisplatin and topotecan in patients with recurrent small-cell lung cancer (SCLC). Thirty-four relapsed patients were treated with cisplatin 20 mg/m2 and topotecan 0.9 mg/m2, both given on days 1-3 every 3 weeks, in a phase II study. Complete response (CR) was achieved in two patients (6%), partial response (PR) in 4 (12%), stable disease in 6 (18%) and progressive disease in 14 (41%). Eight patients (23%) were non-evaluable for response. Among 21 sensitive patients, 2 (9.5%) achieved CR and 3 (14%) PR. Among 13 refractory patients, none achieved CR and only 1 (8%) PR. Median survival was 6.5 months for all patients, 7.8 for sensitive and 6.2 for refractory. Median time to progression (TTP) was 4.4 months for all patients, 5.9 for sensitive and 3.2 for refractory. Grade 3-4 toxicities included anemia (15%), thrombocytopenia (15%), neutropenia (42%), nausea/vomiting (3%), and alopecia (6%). No toxic death occurred. This 3-day schedule was well tolerated, produced modest response rates but good survival and TTP both in sensitive and refractory patients with relapsed SCLC.
ISSN:0344-5704
1432-0843
DOI:10.1007/s00280-005-0034-3